Phreesia, Inc. (NYSE:PHR) is one of the
8 Healthcare Stocks Insiders Are Buying. On April 5, 2026, Wells Fargo lowered the price target on Phreesia, Inc. (NYSE:PHR) to $15 from $25 and maintained an Overweight rating. Wells Fargo said fiscal 2027 revenue guidance “decelerated sharply,” largely driven by the Network segment, citing valuation compression and slower growth, while noting recent Network channel checks were constructive.
On April 1, 2026, Citizens downgraded Phreesia to Market Perform from Outperform without a price target. Citizens said the updated fiscal 2027 revenue outlook was disappointing and raised concerns around the company’s ecosystem thesis, noting growth appears to be “sputtering out” in its largest subscription and related services segment.
20 Countries with the Most Expensive Healthcare in the World
On March 30, 2026, Phreesia reported Q4 adjusted EBITDA of $29.4M compared to $16.4M last year, with revenue of $127.1M versus the $126.6M consensus estimate. CEO Chaim Indig said the company achieved “critical financial milestones,” including positive GAAP net income of $2.3M and exceeding $100M in adjusted EBITDA and $50M in free cash flow for fiscal 2026.
Phreesia, Inc. (NYSE:PHR) provides SaaS-based software and payment solutions for the healthcare industry.
While we acknowledge the potential of PHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
finance.yahoo.com
#Wells #Fargo #Maintains #Overweight #Rating #Phreesia #PHR
